EMA Authorised: Vidaza (azacitidine) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA authorised Vidaza (azacitidine) in the EU for myelodysplastic syndromes and certain leukemias, including chronic myelomonocytic leukemia and acute myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)

Snippet

Status: Authorised. Therapeutic area: Myelodysplastic Syndromes;Leukemia, Myelomonocytic, Chronic;Leukemia, Myeloid, Acute. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 01/11/2024. Accelerated assessment